title: Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients.
abstract: Pancreatic cancer is one of the most aggressive gastrointestinal cancer with less than 10% long-term survivors. The apoptotic pathway deregulation is a postulated mechanism of carcinogenesis of this tumour. The present study investigated the prognostic role of apoptosis and apoptosis-involved proteins in a series of surgically resected pancreatic cancer patients. All patients affected by pancreatic adenocarcinoma and treated with surgical resection from 1988 to 2003 were considered for the study. Patients' clinical data and pathological tumour features were recorded. Survivin and Cox-2 expression were evaluated by immunohistochemical staining. Apoptotic cells were identified using the TUNEL method. Tumour specimen of 67 resected patients was included in the study. By univariate analysis, survival was influenced by Survivin overexpression. The nuclear Survivin overexpression was associated with better prognosis (P = 0.0009), while its cytoplasmic overexpression resulted a negative prognostic factor (P = 0.0127). Also, the apoptotic index was a statistically significant prognostic factor in a univariate model (P = 0.0142). By a multivariate Cox regression analysis, both the nuclear (P = 0.002) and cytoplasmic (P = 0.040) Survivin overexpression maintained the prognostic statistical value. This is the first study reporting a statistical significant prognostic relevance of nuclear and cytoplasmic Survivin overexpression in pancreatic cancer. In particular, patients with high nuclear Survivin staining showed a longer survival, whereas patients with high cytoplasmic Survivin staining had a shorter overall survival.
authors.affiliation: Medical Oncology, University Campus Bio-Medico, Rome, Via Emilio Longoni 83, 00155 Rome, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Tonini
authors.forename: B
authors.initials: B
authors.lastname: Vincenzi
authors.forename: D
authors.initials: D
authors.lastname: Santini
authors.forename: S
authors.initials: S
authors.lastname: Scarpa
authors.forename: T
authors.initials: T
authors.lastname: Vasaturo
authors.forename: C
authors.initials: C
authors.lastname: Malacrino
authors.forename: R
authors.initials: R
authors.lastname: Coppola
authors.forename: P
authors.initials: P
authors.lastname: Magistrelli
authors.forename: D
authors.initials: D
authors.lastname: Borzomati
authors.forename: A
authors.initials: A
authors.lastname: Baldi
authors.forename: A
authors.initials: A
authors.lastname: Antinori
authors.forename: M
authors.initials: M
authors.lastname: Caricato
authors.forename: G
authors.initials: G
authors.lastname: Nuzzo
authors.forename: A
authors.initials: A
authors.lastname: Picciocchi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D017209:Apoptosis / Q000502:physiology*; D021441:Carcinoma, Pancreatic Ductal / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D002467:Cell Nucleus / Q000378:metabolism; D015331:Cohort Studies; D051546:Cyclooxygenase 2; D003593:Cytoplasm / Q000378:metabolism; D005260:Female; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins; D008297:Male; D008565:Membrane Proteins; D008869:Microtubule-Associated Proteins / Q000096:biosynthesis*; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D010180:Pancreatectomy; D010190:Pancreatic Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D011379:Prognosis; D011451:Prostaglandin-Endoperoxide Synthases / Q000096:biosynthesis; D016019:Survival Analysis; D000077022:Survivin
chemical_list: C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; D008565:Membrane Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D000077022:Survivin; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases